Silver Spring, Md. - The FDA Dermatologic and Ophthalmic AdvisoryCommittee, by an 8-2 vote, on May 23 recommended approval of alefacept,a systemic drug for the treatment of chronic plaque psoriasis.
The Weekly Roundup: September 23-27
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
LEO Pharma Presents Extensive Data at EADV
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations
Post Hoc Analysis of Vilobelimab in Hidradenitis Suppurativa Suggests Clinically Meaningful Benefits